[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338071-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338071-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluating-trophinin-associated-protein-as-a-biomarker-of-prognosis-and-therapy-response-in-renal-cell-carcinoma","Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma","","Background: Trophinin associated protein (TROAP) has been linked to some cancers, but its prognostic and treatment-related roles in renal cell carcinoma (RCC) are insufficiently understood. This study investigates TROAP across RCC subtypes. Methods: TROAP expression was examined in pan-cancer TCGA datasets, prognostic value was tested in three TCGA RCC cohorts plus a local cohort, and functional enrichment, genomics analyses, therapeutic response assessment, and in vitro experiments were performed. Results: TROAP is unfavorable, promotes tumor progression, and shows limited association with RCC mutations. Higher TROAP predicts reduced efficacy of nivolumab and everolimus. Conclusions: TROAP is a pivotal biomarker for prognosis and therapy response in RCC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-trophinin-associated-protein-as-a-biomarker-of-prognosis-and-therapy-response-in-renal-cell-carcinoma/338071/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-trophinin-associated-protein-as-a-biomarker-of-prognosis-and-therapy-response-in-renal-cell-carcinoma/338071.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of evaluating TROAP in renal cell carcinoma (RCC)?","Question",{"text":63,"@type":64},"To clarify how TROAP relates to prognosis and therapeutic response in RCC across different subtypes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TROAP expression and prognosis assessed in this study?",{"text":68,"@type":64},"The study analyzed TROAP expression patterns in TCGA pan-cancer cohorts, then validated its prognostic significance in three TCGA RCC cohorts and an additional local cohort.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic implications does higher TROAP expression have?",{"text":72,"@type":64},"Elevated TROAP expression is associated with reduced efficacy of RCC therapies, including nivolumab and everolimus.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338071,1790185509,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Tan et al. BMC Cancer (2024) 24:1021 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12802-9](https://doi.org/10.1186/s12885-024-12802-9)  \nRESEARCH Open Access  \nEvaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma  \nQinglin Tan 1†, Peiliang Kong2†, Guobiao Chen3†, Yanmin Cai 1, Kejun Liu 1, Chen Chen 1, Huiting Mo 1, Yuancheng Huang 1, Jianming Lu4 andYifen Wu 1*  \nAbstract  \nBackground Trophinin Associated Protein (TROAP) has been implicated in some tumors, yet its role in renal cell carcinoma (RCC) remains underexplored. This study aims to elucidate the prognostic and therapeutic implications of TROAP in RCC, encompassing different subtypes.  \nMethods Firstly, we identified the expression patterns ofTROAP across various tumors within theTCGA pan-cancer cohort. Subsequently, the prognostic significance of TROAP was validated in three TCGA RCC cohorts and a local cohort. Finally, we conducted functional enrichment analysis, somatic mutations and copy number variations, assessed therapeutic response cohorts, and performed in vitro experiments to explore the biological characteristics of TROAP.  \nResults TROAP serves as an unfavorable factor in both the TCGA RCC datasets and our local cohort. Functional enrichment analysis and in vitro experiments have demonstrated its oncogene effect in promoting tumor progression. Additionally, the relationship between TROAP expression and gene mutations in RCC appears to be limited. Furthermore, elevated TROAP expression is associated with reduced efficacy of RCC therapies, including nivol umab and everolimus.  \nConclusions Our findings illustrate TROAP as a pivotal biomarker for prognosis and therapeutic response in RCC. Elevated TROAP expression is indicative of aggressive tumor behavior and resistance to conventional therapies, making it a valuable target for personalized treatment strategies in RCC management.  \nKeywords Trophinin associated protein, Renal cell carcinoma, Prognosis, Therapy response, Immunotherapy  \n†Qinglin Tan, Peiliang Kong and Guobiao Chen contributed equally to this work.  \n*Correspondence:  \nYifen Wu  \n[31200195@smu.edu.cn](31200195@smu.edu.cn)  \n1Department of Oncology, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan 523059, China  \n2Department of Pulmonary & Critical Care Medicine, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan 523059, China  \n3Department of Thoracic Surgery, The Tenth Affiliated Hospital of Southern Medical University, Dongguan People’s Hospital), Dongguan 523059, China  \n4Center for medical research on innovation and translation, Institute of Clinical Medicine, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://]","cbCairgZoP7jDrUU","https://ap.wps.com/l/cbCairgZoP7jDrUU","pdf",9123508,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Renal cell carcinoma burden and subtypes\n## Current therapies and need for biomarkers\n## TROAP function and biological context","[{\"question\":\"What is the main purpose of evaluating TROAP in renal cell carcinoma (RCC)?\",\"answer\":\"To clarify how TROAP relates to prognosis and therapeutic response in RCC across different subtypes.\"},{\"question\":\"How was TROAP expression and prognosis assessed in this study?\",\"answer\":\"The study analyzed TROAP expression patterns in TCGA pan-cancer cohorts, then validated its prognostic significance in three TCGA RCC cohorts and an additional local cohort.\"},{\"question\":\"What therapeutic implications does higher TROAP expression have?\",\"answer\":\"Elevated TROAP expression is associated with reduced efficacy of RCC therapies, including nivolumab and everolimus.\"}]","Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma | PDF",1790021824,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b80023e3631a92a7584c3c0e9231ed6d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41c8c01e61ece3c795e36bd49953d4f4.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/743956aae76f30908787e756643da03a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1d425d705404196ab4f52ed0f35ddcb.webp",980,1306]